China National Medicines Future Growth

Future criteria checks 1/6

China National Medicines is forecast to grow earnings and revenue by 9.1% and 8.9% per annum respectively. EPS is expected to grow by 9.5% per annum. Return on equity is forecast to be 12.7% in 3 years.

Key information

9.1%

Earnings growth rate

9.5%

EPS growth rate

Healthcare earnings growth	23.0%
Revenue growth rate	8.9%
Future return on equity	12.7%
Analyst coverage	Low
Last updated	12 Nov 2024

Recent future growth updates

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25

Recent updates

We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

Nov 12

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Sep 26

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Sep 10

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28

Earnings and Revenue Growth Forecasts

SHSE:600511 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	62,516	2,688	N/A	2,871	2
12/31/2025	57,764	2,458	N/A	2,208	3
12/31/2024	52,810	2,293	N/A	1,902	2
9/30/2024	51,195	2,165	1,540	1,688	N/A
6/30/2024	50,312	2,162	1,688	1,827	N/A
3/31/2024	50,592	2,191	2,008	2,151	N/A
12/31/2023	49,696	2,146	2,582	2,727	N/A
9/30/2023	47,486	1,995	2,466	2,602	N/A
6/30/2023	47,632	2,086	2,040	2,194	N/A
3/31/2023	45,665	2,005	2,429	2,560	N/A
12/31/2022	45,499	1,964	2,265	2,395	N/A
9/30/2022	46,719	1,884	1,336	1,460	N/A
6/30/2022	46,399	1,850	1,081	1,185	N/A
3/31/2022	47,185	1,830	1,746	1,851	N/A
12/31/2021	46,469	1,754	1,862	1,957	N/A
9/30/2021	45,559	1,680	1,085	1,170	N/A
6/30/2021	44,923	1,529	1,129	1,197	N/A
3/31/2021	42,512	1,449	1,187	1,247	N/A
12/31/2020	40,379	1,383	1,233	1,302	N/A
9/30/2020	41,046	1,537	1,058	1,125	N/A
6/30/2020	41,153	1,469	1,922	1,997	N/A
3/31/2020	42,805	1,549	1,399	1,477	N/A
12/31/2019	44,644	1,604	1,690	1,776	N/A
9/30/2019	42,673	1,525	1,037	1,139	N/A
6/30/2019	40,991	1,523	1,024	1,159	N/A
3/31/2019	39,659	1,436	-33	103	N/A
12/31/2018	38,740	1,404	849	982	N/A
9/30/2018	37,994	1,256	2,457	2,576	N/A
6/30/2018	37,452	1,224	N/A	2,058	N/A
3/31/2018	36,653	1,163	N/A	1,424	N/A
12/31/2017	36,285	1,141	N/A	1,074	N/A
9/30/2017	36,072	1,060	N/A	63	N/A
6/30/2017	35,540	1,044	N/A	-85	N/A
3/31/2017	40,103	1,101	N/A	488	N/A
12/31/2016	34,611	990	N/A	1,043	N/A
9/30/2016	28,613	887	N/A	461	N/A
6/30/2016	22,813	752	N/A	716	N/A
3/31/2016	12,408	527	N/A	445	N/A
12/31/2015	12,078	513	N/A	440	N/A
9/30/2015	12,065	499	N/A	307	N/A
6/30/2015	11,894	499	N/A	424	N/A
3/31/2015	11,773	490	N/A	394	N/A
12/31/2014	11,538	483	N/A	219	N/A
9/30/2014	11,177	465	N/A	338	N/A
6/30/2014	10,824	457	N/A	240	N/A
3/31/2014	10,408	431	N/A	204	N/A
12/31/2013	10,081	412	N/A	186	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600511's forecast earnings growth (9.1% per year) is above the savings rate (2.8%).

Earnings vs Market: 600511's earnings (9.1% per year) are forecast to grow slower than the CN market (26.2% per year).

High Growth Earnings: 600511's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600511's revenue (8.9% per year) is forecast to grow slower than the CN market (13.8% per year).

High Growth Revenue: 600511's revenue (8.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600511's Return on Equity is forecast to be low in 3 years time (12.7%).

China National Medicines Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Price target increased by 14% to CN¥46.58

Price target decreased to CN¥39.20

Recent updates

We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings released: EPS: CN¥0.64 (vs CN¥0.63 in 3Q 2023)

China National Medicines Corporation Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 16%

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Now 22% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: CN¥0.72 (vs CN¥0.76 in 2Q 2023)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

China National Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 22, 2024

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Now 20% undervalued

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Dividend increased to CN¥0.85

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

First quarter 2024 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in 1Q 2023)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China National Medicines Corporation Ltd., Annual General Meeting, Apr 25, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

China National Medicines (SHSE:600511) Could Easily Take On More Debt

China National Medicines Corporation Ltd. to Report Fiscal Year 2023 Results on Mar 21, 2024

Third quarter 2023 earnings released: EPS: CN¥0.63 (vs CN¥0.76 in 3Q 2022)

China National Medicines Corporation Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.65 in 2Q 2022)

Price target increased by 14% to CN¥46.58

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.76 (vs CN¥0.71 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.65 (vs CN¥0.62 in 2Q 2021)

China National Medicines Corporation Ltd.(XSSC:600511) dropped from S&P Global BMI Index

China National Medicines Corporation Ltd.(XSSC:600511) dropped from FTSE All-World Index (USD)

Price target decreased to CN¥39.20

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Now 23% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.71 (vs CN¥0.51 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.62 (vs CN¥0.51 in 2Q 2020)

Upcoming dividend of CN¥0.55 per share

First quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.31 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.83 (vs CN¥2.11 in FY 2019)

New 90-day low: CN¥36.33

New 90-day low: CN¥41.32

China National Medicines Corporation Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

China National Medicines Corporation Ltd. Announces Resignation of Li Hui as A Director, the General Manager, A Member of the Strategy Committee and A Member of the Audit Committee

Investor sentiment deteriorated over the past week

Market bids up stock over the past week

New 90-day high: CN¥50.10

Third quarter earnings released

China National Medicines Corporation Ltd. to Report Q3, 2020 Results on Oct 22, 2020

Earnings released

New 90-day high - CN¥52.00

China National Medicines Corporation Ltd. to Report First Half, 2020 Results on Aug 19, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies